(WEX) Wex - Overview
Stock: Fleet Cards, Corporate Payments, Benefits Software
| Risk 5d forecast | |
|---|---|
| Volatility | 49.1% |
| Relative Tail Risk | -10.2% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.15 |
| Alpha | -15.22 |
| Character TTM | |
|---|---|
| Beta | 1.528 |
| Beta Downside | 1.629 |
| Drawdowns 3y | |
|---|---|
| Max DD | 53.15% |
| CAGR/Max DD | -0.12 |
EPS (Earnings per Share)
Revenue
Description: WEX Wex January 09, 2026
WEX Inc. (NYSE: WEX) runs a diversified commerce platform that spans three primary segments: Mobility, Corporate Payments, and Benefits Solutions. The Mobility segment delivers fleet-vehicle payment processing, account-management services, and analytics to commercial fleets and government agencies, leveraging both direct sales and co-branded/private-label partnerships. Corporate Payments offers embedded payment capabilities, accounts-payable automation, and spend-management tools to customers in travel, fintech, insurance, consumer-bill-pay, and media verticals. Benefits Solutions provides a SaaS platform for consumer-directed health benefits-including HSAs, HSAs, and COBRA administration-served through third-party administrators, payroll providers, and health plans.
Based on the FY 2023 earnings release, WEX generated $2.0 billion in revenue, with the Mobility segment contributing roughly 55 % and posting a 7 % year-over-year growth rate, driven by increasing demand for electric-vehicle fleet financing and higher transaction volumes. The Corporate Payments unit grew 9 % YoY, reflecting broader corporate spend-management trends and the acceleration of digital invoicing post-COVID-19. Benefits Solutions, while smaller (≈ 15 % of total revenue), posted a 12 % increase, underscoring the continued shift toward consumer-direct health accounts as employers seek cost-containment. Key economic drivers include corporate capital-expenditure cycles, regulatory changes in healthcare benefits (e.g., HSA contribution limits), and the macro-trend toward embedded finance in non-financial industries.
For a deeper, data-driven look at how these trends translate into valuation metrics, you might explore the analytics available on ValueRay.
Piotroski VR‑10 (Strict, 0-10) 4.0
| Net Income: 304.2m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.02 > 0.02 and ΔFCF/TA -0.39 > 1.0 |
| NWC/Revenue: 16.02% < 20% (prev 7.16%; Δ 8.86% < -1%) |
| CFO/TA 0.03 > 3% & CFO 454.3m > Net Income 304.2m |
| Net Debt (3.95b) to EBITDA (947.8m): 4.17 < 3 |
| Current Ratio: 1.05 > 1.5 & < 3 |
| Outstanding Shares: last quarter (35.0m) vs 12m ago -10.26% < -2% |
| Gross Margin: 57.77% > 18% (prev 0.61%; Δ 5716 % > 0.5%) |
| Asset Turnover: 19.20% > 50% (prev 19.73%; Δ -0.53% > 0%) |
| Interest Coverage Ratio: 2.75 > 6 (EBITDA TTM 947.8m / Interest Expense TTM 240.6m) |
Altman Z'' 1.13
| A: 0.03 (Total Current Assets 9.71b - Total Current Liabilities 9.29b) / Total Assets 14.40b |
| B: 0.16 (Retained Earnings 2.29b / Total Assets 14.40b) |
| C: 0.05 (EBIT TTM 661.4m / Avg Total Assets 13.86b) |
| D: 0.09 (Book Value of Equity 1.23b / Total Liabilities 13.16b) |
| Altman-Z'' Score: 1.13 = BB |
Beneish M -2.96
| DSRI: 1.10 (Receivables 3.36b/3.01b, Revenue 2.66b/2.63b) |
| GMI: 1.05 (GM 57.77% / 60.52%) |
| AQI: 0.90 (AQ_t 0.31 / AQ_t-1 0.34) |
| SGI: 1.01 (Revenue 2.66b / 2.63b) |
| TATA: -0.01 (NI 304.2m - CFO 454.3m) / TA 14.40b) |
| Beneish M-Score: -2.96 (Cap -4..+1) = A |
What is the price of WEX shares?
Over the past week, the price has changed by -2.94%, over one month by -0.01%, over three months by +15.59% and over the past year by -1.07%.
Is WEX a buy, sell or hold?
- StrongBuy: 2
- Buy: 1
- Hold: 13
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the WEX price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 169.4 | 7.4% |
| Analysts Target Price | 169.4 | 7.4% |
WEX Fundamental Data Overview February 12, 2026
P/E Forward = 9.4429
P/S = 2.1349
P/B = 4.6107
P/EG = 1.5745
Revenue TTM = 2.66b USD
EBIT TTM = 661.4m USD
EBITDA TTM = 947.8m USD
Long Term Debt = 3.53b USD (from longTermDebt, last quarter)
Short Term Debt = 1.33b USD (from shortTermDebt, last quarter)
Debt = 4.86b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 3.95b USD (from netDebt column, last quarter)
Enterprise Value = 9.63b USD (5.68b + Debt 4.86b - CCE 905.8m)
Interest Coverage Ratio = 2.75 (Ebit TTM 661.4m / Interest Expense TTM 240.6m)
EV/FCF = 32.20x (Enterprise Value 9.63b / FCF TTM 299.2m)
FCF Yield = 3.11% (FCF TTM 299.2m / Enterprise Value 9.63b)
FCF Margin = 11.24% (FCF TTM 299.2m / Revenue TTM 2.66b)
Net Margin = 11.43% (Net Income TTM 304.2m / Revenue TTM 2.66b)
Gross Margin = 57.77% ((Revenue TTM 2.66b - Cost of Revenue TTM 1.12b) / Revenue TTM)
Gross Margin QoQ = 54.44% (prev 60.35%)
Tobins Q-Ratio = 0.67 (Enterprise Value 9.63b / Total Assets 14.40b)
Interest Expense / Debt = 1.21% (Interest Expense 58.8m / Debt 4.86b)
Taxrate = 23.45% (25.8m / 110.0m)
NOPAT = 506.3m (EBIT 661.4m * (1 - 23.45%))
Current Ratio = 1.05 (Total Current Assets 9.71b / Total Current Liabilities 9.29b)
Debt / Equity = 3.94 (Debt 4.86b / totalStockholderEquity, last quarter 1.23b)
Debt / EBITDA = 4.17 (Net Debt 3.95b / EBITDA 947.8m)
Debt / FCF = 13.21 (Net Debt 3.95b / FCF TTM 299.2m)
Total Stockholder Equity = 1.04b (last 4 quarters mean from totalStockholderEquity)
RoA = 2.19% (Net Income 304.2m / Total Assets 14.40b)
RoE = 29.38% (Net Income TTM 304.2m / Total Stockholder Equity 1.04b)
RoCE = 14.48% (EBIT 661.4m / Capital Employed (Equity 1.04b + L.T.Debt 3.53b))
RoIC = 8.01% (NOPAT 506.3m / Invested Capital 6.32b)
WACC = 6.65% (E(5.68b)/V(10.54b) * Re(11.54%) + D(4.86b)/V(10.54b) * Rd(1.21%) * (1-Tc(0.23)))
Discount Rate = 11.54% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -8.60%
[DCF Debug] Terminal Value 82.95% ; FCFF base≈311.1m ; Y1≈302.3m ; Y5≈302.3m
Fair Price DCF = 96.31 (EV 7.25b - Net Debt 3.95b = Equity 3.30b / Shares 34.3m; r=6.65% [WACC]; 5y FCF grow -3.93% → 2.90% )
EPS Correlation: 35.89 | EPS CAGR: 9.95% | SUE: 1.64 | # QB: 3
Revenue Correlation: 77.04 | Revenue CAGR: 7.25% | SUE: 1.03 | # QB: 2
EPS next Quarter (2026-03-31): EPS=3.92 | Chg30d=-0.053 | Revisions Net=-2 | Analysts=13
EPS current Year (2026-12-31): EPS=17.54 | Chg30d=-0.096 | Revisions Net=-3 | Growth EPS=+8.9% | Growth Revenue=+2.7%
EPS next Year (2027-12-31): EPS=19.43 | Chg30d=-0.292 | Revisions Net=-5 | Growth EPS=+10.8% | Growth Revenue=+5.1%